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Abstract
Introduction: Lipid-lowering agents affect adipose tissue function. No study has investigated the role of age in the effects of hypolipi-
daemic agents on plasma adipokines.
Material and methods: The study was a retrospective analysis of data of 65 hypercholesterolaemic patients treated for 90 days with 
simvastatin, ezetimibe, or simvastatin/ezetimibe combination therapy. Circulating levels of leptin, adiponectin, visfatin, and tumour ne-
crosis factor a (TNF-a), as well as high-sensitivity C-reactive protein (hsCRP) were assessed separately for patients aged between 35 and 
50 years and between 51 and 65 years, at the beginning and at the end of treatment.
Results: Patients in the age between 51 and 65 years had higher plasma levels of TNF-a and hsCRP, and lower plasma levels of adiponectin 
than patients aged between 35 and 50 years. In both age groups, simvastatin reduced plasma levels of hsCRP, leptin, visfatin, and TNF-a 
and increased circulating levels of adiponectin. This effect was particularly pronounced if simvastatin was administered in combination 
with ezetimibe. Ezetimibe alone increased plasma adiponectin and reduced plasma levels of leptin and hsCRP only in older adults. Ir-
respectively of age, ezetimibe administered alone did not affect visfatin and TNF-a. The effect of simvastatin on plasma hsCRP and the 
investigated adipokines did not differ between both groups. In turn, the effect of ezetimibe and simvastatin/ezetimibe combination therapy 
on leptin, adiponectin, and hsCRP was stronger in older than in younger adults. 
Conclusions: Our results show that age may partially determine the effect of ezetimibe, but not of simvastatin, on adipose tissue func-
tion. (Endokrynol Pol 2016; 67 (3): 271–276)
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Streszczenie
Wstęp: Leki hipolipemiczne wpływają na funkcję tkanki tłuszczowej. Jak dotąd nie przeprowadzono żadnego badania oceniającego 
znaczenie wieku dla działania leków hipolipemicznych na stężenie adipokin w osoczu.
Materiał i metody: Badanie stanowiło retrospektywną analizę wyników 65 pacjentów z hipercholesterolemią leczonych przez 90 dni 
simwastatyną, ezetimibem lub oboma tymi lekami łącznie. Stężenie w osoczu leptyny, adiponektyny, wisfatyny, czynnika martwicy 
nowotworów a (TNF-a) oraz wysoko czułego białka C-reaktywnego (hsCRP) oceniano oddzielnie dla chorych w wieku od 35 do 50 lat 
oraz od 51 do 65 lat przed rozpoczęciem i po zakończeniu 90-dniowego protokołu badania.
Wyniki: Pacjenci w wieku 51–65 lat charakteryzowali się wyższym stężeniem w osoczu TNF-a i hsCRP oraz niższym stężeniem adiponek-
tyny niż chorzy młodsi. W obu grupach wiekowych simwastatyna obniżała stężenie hsCRP, leptyny, wisfatyny, TNF-a oraz zwiększała 
stężenie adiponektyny. Wpływ na stężenie hormonów tkanki tłuszczowej i hsCRP był szczególnie wyraźnie wyrażony w przypadku 
łącznego stosowania simwastatyny z ezetimibem. Ezetimib zastosowany w monoterapii zwiększał stężenie adiponektyny i obniżał stężenie 
leptyny oraz hsCRP w grupie pacjentów pomiędzy 51. a 65. rokiem życia, ale nie w grupie chorych młodszych. Niezależnie od grupy 
wiekowej, nie obserwowano wpływu stosowania ezetimibu na stężeniem wisfatyny i TNF-a. Nie obserwowano różnic w stężeniu hsCRP 
oraz ocenianych adipokin pomiędzy obiema grupami wiekowymi w przypadku monoterapii simwastatyną. Z kolei wpływ ezetimibu 
i leczenia skojarzonego na stężenie leptyny, adiponektyny i hsCRP był bardziej wyrażonych w grupie starszych niż młodszych pacjentów.
Wnioski: Wyniki badania przemawiają za tym, że wpływ ezetimibu, a nie simwastatyny, na stężenie adipokin jest częściowo uwarunko-
wany wiekiem pacjenta. (Endokrynol Pol 2016; 67 (3): 271–276)
Słowa kluczowe: wiek; simwastatyna; ezetimib; hipercholesterolemia; leptyna; adiponektyna; wisfatyna; czynnik martwicy nowotworów a 
(TNF-a)
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Abbreviations
CRP — C-reactive protein
HDL — high-density lipoprotein
HMG-CoA — 3-hydroxy-3-methylglutaryl coenzyme A
HOMA-IR — the homeostatic model assessment of 
insulin resistance ratio
hsCRP — high sensitivity C-reactive protein
LDL — low-density lipoprotein
NPC1L1 — Niemann-Pick C1-Like 1 transporter
TNF-a — tumour necrosis factor-a
Introduction
Adipose tissue, for a long time perceived as a passive 
lipid storage depot, is a highly active metabolic and en-
docrine organ expressing and secreting a large number 
of mediators that affect metabolism, inflammation, 
and coagulation [1, 2]. Its dysfunction, reflected by 
abnormal plasma levels of adipose tissue hormones 
(adipokines), seems to play an important role in the 
pathogenesis of obesity, insulin resistance, type 2 diabe-
tes, and possibly also of cardiovascular disorders [3–7]. 
Aging is known to be associated with an increased 
risk of insulin resistance, weight, and adiposity gain [8, 
9]. It is characterised by fat redistribution, decreased 
preadipocyte number, impaired preadipocyte function, 
and increased macrophage infiltration of adipose tissue, 
the consequence of which may be abnormal secretion 
of adipokines [10]. Older adults are more prone to the 
development of metabolic disorders, including lipid 
abnormalities, and cardiovascular disorders [11, 12]. 
These findings, suggesting the existence of adipose 
tissue dysfunction in the elderly, seem to be important 
from a clinical point of view. There are some data in-
dicating that adipokine production and/or metabolism 
may determine lifespan. Centenarians, representing a 
healthy aging phenotype, were characterised by higher 
plasma adiponectin and lower plasma leptin levels 
than younger older and obese subjects [13]. Moreover, 
serum levels of total adiponectin, as well as its high mo-
lecular weight and middle molecular weight isoforms, 
were significantly higher in octogenarians than in cor-
responding middle-aged control groups [14]. Finally, 
dysregulation of leptin, adiponectin, and TNF-a was 
found to be a strong marker of poor prognosis in cen-
tenarians, independent of conventional risk factors [15].
3-hydroxy-3-methyl-glutaryl-CoA (HMC-CoA) re-
ductase inhibitors (statins), being the drugs of choice 
for the treatment of elevated cholesterol levels and used 
by most patients with cardiovascular diseases, are fre-
quently prescribed to older adults [16, 17]. The results of 
our previous studies showed that adipose tissue is one 
of the targets for hypolipidaemic agents. Atorvastatin 
and fenofibric acid were found to reduce adipokine 
release from cultures of human adipocytes [18], as well 
as cultures of visceral and subcutaneous adipose tis-
sue [19]. In turn, simvastatin, administered alone or in 
combination with ezetimibe, decreased plasma levels of 
leptin, visfatin, and TNF-a and increased plasma levels 
of adiponectin [20–22], and this effect was present in 
both men and women [23]. 
To the best of our knowledge, no previous study 
has investigated whether the impact of hypolipidae-
mic agents depends on age. Therefore, in this study 
we decided to compare the effects of simvastatin and 
ezetimibe, administered alone or in combination, on 
plasma adipokine levels between different age groups. 
Material and methods
The study was a retrospective analysis of the previous 
studies of our research team [20, 22, 24]. The study 
protocol was approved by the local ethical committee, 
and all patients participating in the original studies gave 
their written informed consent before the beginning 
of the study. Patients (35–65 years old) were eligible 
for the study if they met the criteria of isolated hyper-
cholesterolaemia (total plasma cholesterol more than 
200 mg/dL, LDL cholesterol more than 130 mg/dL, and 
triglycerides less than 150 mg/dL) and complied with 
lifestyle intervention for at least three months before 
the beginning of the study. We excluded patients with 
untreated stage 2 or 3 hypertension (according to the 
2003 European Society of Hypertension–European 
Society of Cardiology guidelines), symptomatic con-
gestive heart failure, diabetes, autoimmune disorders, 
acute and chronic inflammatory processes, thyroid 
diseases, chronic pancreatitis, impaired renal or hepatic 
function and body mass index more than 35 kg/m2, as 
well as patients treated within three months preceding 
the study with drugs interfering with statins and/or 
ezetimibe. During the study, all patients continued to 
comply with the lifestyle modification (total fat intake 
< 30% of total energy intake, saturated fat intake < 7% 
of energy consumed, cholesterol intake < 200 mg per 
day, an increase in fibre intake to 15 g per 1000 kcal, 
moderate to vigorous exercise for at least 30 minutes 
per day), as well as were treated with constant doses 
of simvastatin (40 mg, n = 23) [22], ezetimibe (10 mg, 
n = 21) [24], or simvastatin (40 mg) together with 
ezetimibe (10 mg) (n = 21) [22] for 90 days. 
Venous blood samples were taken from the antecu-
bital vein, after a 12-hour overnight fast, in a quiet, tem-
perature-controlled room (24–25°C) between 8.00 and 
9.00 a.m. (to avoid possible circadian fluctuations in the 
parameters studied), before and at the end of the study. 
Analysis was performed by a person blinded to subject 
273
Endokrynologia Polska 2016; 67 (3)
PR
A
C
E 
O
RY
G
IN
A
LN
E
identity and clinical details. All samples were run in 
duplicate and final results were averaged. Plasma lipids 
(total cholesterol, HDL cholesterol, LDL cholesterol, and 
triglycerides), glucose, and insulin were assessed by rou-
tine laboratory techniques (bioMerieux France; Incstar 
Corporation, Stillwater, MN, USA; Beckman, Palo Alto, 
CA, USA; Linco Research Inc., St Charles, MO, USA). 
The homeostatic model assessment of IR (HOMA-IR) 
was calculated as the product of glucose and insulin 
levels, divided by 405. Plasma C-reactive protein levels 
(hsCRP) were assessed by a highly sensitive enzyme 
immunoassay using monoclonal antibodies (MP Bio-
medicals, Orangeburg, NY). Circulating levels of leptin, 
adiponectin, visfatin, and TNF-a were determined by 
enzyme immunoassay using reagents purchased from 
TECOmedical Group (Sissach, Switherland), Phoenix 
Pharmaceuticals (Burlingame, CA) and R&D Systems 
(McKinley Place, N.E. Minneapolis, MN). The minimum 
detectable levels for the assessed parameters were: 
0.1 mg/L, 7.8 pg/mL, 0.246 ng/mL, 6.1 pg/mL, and 1.6 pg/mL, 
respectively for hsCRP, leptin, adiponectin, visfatin, 
and TNF-a. The intra- and interassay coefficients of 
variation for the assessed markers were less than 
5.5 and 8.7%, respectively.
The normality of distribution was determined us-
ing the Shapiro-Wilk test. Because of skewed distribu-
tions, natural logarithmic transformations were done 
for triglycerides, HOMA-IR, hsCRP, and adipokines. 
Comparisons between the groups were carried out 
using the t-test for independent samples. Student’s 
paired t-test was used to determine within group dif-
ferences between pre- and post-tests. c2 test was used 
to test categorical variables. Correlations were assessed 
using Kendall’s tau test. Differences were considered 
statistically significant at p < 0.05.
Results
Sex distribution, percentage of smokers, blood pressure, 
as well as the mean values of plasma HDL cholesterol, 
triglycerides, glucose, leptin, and visfatin were all 
comparable between both age groups (Table I). Baseline 
adiponectin levels were higher, while baseline TNF-a 
and hsCRP levels were lower in patients aged between 
35 and 50 years than in patients aged between 51 and 
65 years. The older adults had insignificantly higher 
levels of total cholesterol (p = 0.068), LDL cholesterol 
(p = 0.071), as well as insignificantly higher values 
of HOMA-IR (p = 0.086) and of body mass index 
(p = 0.095).
Simvastatin, ezetimibe, and the combination 
therapy reduced total and LDL cholesterol, with no dif-
ference between the studied populations. Nor did they 
affect cholesterol and triglycerides. Moreover, ezetimibe 
alone or in combination with simvastatin tended 
to reduce HOMA-IR (ezetimibe: younger patients — 
p = 0.068, older patients — p = 0.071; combination 
therapy: younger patients — p = 0.065, older patients 
— p = 0.075) (Table II–IV). In both age populations, 
simvastatin administered alone reduced plasma levels 
of hsCRP, leptin, visfatin, and TNF-a, and increased 
circulating levels of adiponectin (Table II). In patients 
between 51 and 65 years old, but not in the other age 
group of patients, ezetimibe reduced plasma leptin 
and hsCRP, but it increased circulating adiponectin. Ir-
respectively of age, ezetimibe did not affect visfatin and 
TNF-a (Table III). Simvastatin administered together 
with ezetimibe decreased plasma levels of hsCRP, lep-
tin, visfatin, and TNF-a, but increased plasma levels 
of adiponectin (Table IV). The impact of statin therapy 
on the investigated markers did not depend on age 
(Table II). In turn, the effect of ezetimibe (Table III) and 
simvastatin/ezetimibe combination therapy (Table IV) 
on hsCRP, leptin, and adiponectin, but not on the re-
maining variables, was more pronounced in the older 
than in the younger patients.
At the beginning of the study, there were positive 
correlations between plasma levels of leptin, visfatin, 
and TNF-a and total cholesterol, LDL cholesterol, 
HOMA-IR, and hsCRP (younger patients: r values 
Table I. Baseline characteristics of patients
Tabela I. Wyjściowa charakterystyka pacjentów
Younger  
adults*
Older  
adults**
Number of patients 31 34
Age [years; mean (SD)] 43 (4) 58 (4)b
Women (%) 41 42
Smokers (%) 26 24
Body mass index [kg/m2; mean (SD)] 25,5 (3,2) 27,9 (3,5)
Waist circumference [cm; mean (SD)] 95 (8) 98 (8)
Total cholesterol [mg/dL; mean (SD)] 242 (29) 264 (27)
LDL cholesterol [mg/dL; mean (SD)] 174 (21) 188 (19)
HDL cholesterol [mg/dL; mean (SD)] 47 (8) 43 (7)
Triglycerides [mg/dL; mean (SD)] 123 (12) 130 (10)
Glucose [mg/dL; mean (SD)] 94 (6) 96 (5)
HOMA-IR [mean (SD)] 2.5 (0.7) 3.1 (0.8)
hsCRP [mg/L; mean (SD)] 3.1 (0.7) 3.9 (0.8)a
Leptin [ng/mL; mean (SD)] 24.5 (5.6) 25.5 (5.8)
Adiponectin [mg/L; mean (SD)] 6.2 (1.4) 4.7 (1.1)a
Visfatin [ng/mL; mean (SD)] 20.8 (4.0) 22.1 (3.4)
TNF-a [pg/mL; mean (SD)] 14.8 (2.9) 17.8 (2.6)a
*35–50 years old; **51–65 years old; ap < 0.05; bp < 0.001 vs. younger adults
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between 0.30 [p < 0.05] and 0.64 [p < 0.001]; older 
patients: r values between 0.34 [p < 0.05] and 0.56 
[p < 0.001]), as well as negative correlations between 
plasma levels of adiponectin and total cholesterol, LDL 
cholesterol, HOMA-IR, and hsCRP (younger patients: 
r values between –0.35 [p < 0.01] and –0.60 [p < 0.001]; 
older patients: r values between –0.37 [p < 0.01] and 
–0.58 [p < 0.001]). Moreover, plasma hsCRP, TNF-a, and 
adiponectin, but not the remaining variables, correlated 
with age (hsCRP: r = 0.40, p < 0.001; TNF-a: r = 0.37, 
p < 0.01; adiponectin: r = –0.42, p < 0.001). In both age 
populations, the effect of simvastatin, ezetimibe, and 
combination therapy on the investigated adipokines 
correlated with its impact on hsCRP (younger patients: 
r values between 0.31 [p < 0.05] and 0.55 [p < 0.001]; 
older patients: r values between 0.35 [p < 0.01] and 
0.61 [p < 0.001]). Moreover, the effect of ezetimibe and 
simvastatin/ezetimibe combination therapy on plasma 
adipokines and hsCRP correlated weakly with the 
action on HOMA-IR (ezetimibe: younger patients — 
r values between 0.30 [p < 0.05] and 0.38 [p < 0.01]; 
older patients - r values between 0.29 [p < 0.05] and 
0.37 [p < 0.01]; combination therapy: younger patients 
— r values between 0.28 [p < 0.05] and 0.36 [p < 0.01]; 
older patients — r values between 0.29 [p < 0.05] and 
0.35 [p < 0.01]). The effect of ezetimibe and simvasta-
Table II. The effect of 90-day simvastatin treatment on plasma 
lipids, glucose metabolism markers, and circulating levels 
of high sensitivity C-reactive protein and the investigated 
adipokines in different age groups of hypercholesterolaemic 
patients
Tabela II. Wpływ 90-dniowego stosowania simwastatyny 
na stężenie lipidów, markery gospodarki węglowodanowej 
oraz stężenie białka C-reaktywnego i ocenianych adipokin 
w różnych grupach wiekowych u pacjentów z izolowaną 
hipercholesterolemią
Younger adults* 
(n = 10)
Older adults** 
(n = 13)
DTotal cholesterol [%; mean (SD)] –24 (8)c –27 (6)c
DLDL cholesterol [%; mean (SD)] –29 (7)c –32 (7)c
DHDL cholesterol [%; mean (SD)] 6 (8) 7 (10)
DTriglycerides [%; mean (SD)] –14 (8) –10 (7)
DGlucose [%; mean (SD)] 2 (3) 0 (2)
DHOMA-IR [%; mean (SD)] 5 (6) 5 (7)
DhsCRP [%; mean (SD)] –42 (10)c –39 (8)c
DLeptin [%; mean (SD)] –35 (11)c –38 (10)c
DAdiponectin [%; mean (SD)] 64 (12)c 75 (18)c
DVisfatin [%; mean (SD)] –29 (12)a –28 (11)a
DTNF-a [%; mean (SD)] –36 (11)c –34 (11)b
*35–50 years old; **51–65 years old. The data show percentage changes from 
the respective baseline value. ap < 0.05, bp < 0.01, cp < 0.001 post-treatment 
vs. baseline value
Table III. The effect of 90-day ezetimibe treatment on plasma 
lipids, glucose metabolism markers, and circulating levels 
of high sensitivity C-reactive protein and the investigated 
adipokines in different age groups of hypercholesterolaemic 
patients
Tabela III. Wpływ 90-dniowego stosowania ezetimibu na 
stężenie lipidów, markery gospodarki węglowodanowej 
oraz stężenie białka C-reaktywnego i ocenianych adipokin 
w różnych grupach wiekowych u pacjentów z izolowaną 
hipercholesterolemią 
Younger adults* 
(n = 11)
Older adults** 
(n = 10)
DTotal cholesterol [%; mean (SD)] –22 (6)b –24 (7)b
DLDL cholesterol [%; mean (SD)] –26 (7)b –28 (7)b
DHDL cholesterol [%; mean (SD)] 4 (8) 3 (9)
DTriglycerides [%; mean (SD)] –8 (10) –11 (14)
DGlucose [%; mean (SD)] –3 (2) –2 (3)
DHOMA-IR [%; mean (SD)] –16 (7) –18 (8)
DhsCRP [%; mean (SD)] –8 (12) –32 (10)a, c
DLeptin [%; mean (SD)] –8 (14) –35 (3)a, c
DAdiponectin [%; mean (SD)] 10 (12) 41 (13)a, c
DVisfatin [%; mean (SD)] –27 (13) –25 (11)
DTNF-a [%; mean (SD)] –20 (14) –22 (11)
*35–50 years old; **51–65 years old. The data show percentage changes from 
the respective baseline value. ap < 0.05, bp < 0.001 post-treatment vs. baseline 
value; cp < 0.05 vs. younger adults
Table IV. The effect of 90-day simvastatin/ezetimibe 
combination therapy on plasma lipids, glucose metabolism 
markers, and circulating levels of high sensitivity C-reactive 
protein and the investigated adipokines in different age 
groups of hypercholesterolaemic patients
Tabela IV. Wpływ 90-dniowego stosowania simwastatyny 
wraz z ezetimibem na stężenie lipidów, markery gospodarki 
węglowodanowej oraz stężenie białka C-reaktywnego 
i ocenianych adipokin w różnych grupach wiekowych 
u pacjentów z izolowaną hipercholesterolemią
Younger adults* 
(n = 10)
Older adults* 
(n = 11)
DTotal cholesterol [%; mean (SD)] –39 (10)a –40 (11)a
DLDL cholesterol [%; mean (SD)] –46 (12)a –49 (13)a
DHDL cholesterol [%; mean (SD)] 17 (9) 16 (8)
DTriglycerides [%; mean (SD)] –19 (15) –18 (14)
DGlucose [%; mean (SD)] –2 (3) –3 (2)
DHOMA-IR [%; mean (SD)] –18 (–12) –20 (–12)
DhsCRP [%; mean (SD)] –58 (14)a –78 (12)a, b
DLeptin [%; mean (SD)] –50 (19)a –78 (11)a, b
DAdiponectin [%; mean (SD)] 82 (20)a 112 (28)a, b
DVisfatin [%; mean (SD)] –53 (12)a –61 (20)a
DTNF-a [%; mean (SD)] –58 (15)a –61 (18)a
*35–50 years old; **51–65 years old. The data show percentage changes from 
the respective baseline value. ap < 0.001 post-treatment vs. baseline value;  
bp < 0.05 vs. younger adults
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tin/ezetimibe combination therapy on hsCRP, leptin 
and adiponectin correlated with the age of patients 
(ezetimibe - hsCRP: r = 0.39, p < 0.01; leptin: r = 0.37, 
p < 0.01; adiponectin: r = 0.39, p < 0.01; combination 
therapy: hsCRP: r = 0.37, p < 0.01; leptin: r = 0.32, 
p < 0.05; adiponectin: r = 0.35, p < 0.01). No other 
correlations were found in both baseline conditions 
and after treatment. 
Discussion
The results of this study show differences in plasma 
levels of adiponectin and TNF-a, but not of other 
adipose tissue products, between patients belonging 
to both of the studied age populations. This observa-
tion is in agreement with the results of other authors 
[25], who observed increased plasma TNF-a levels and 
normal leptin levels in older adults. Also, in the study 
by Paolisso et al. [26], advancing age strongly correlated 
with plasma TNF-a concentration, and this correlation 
was independent of sex and body fat. A strength of our 
study was the strict inclusion criteria and the similar 
baseline characteristics of both analysed subgroups of 
patients. Although older and younger patients varied 
in body mass index, this does not seem to explain the 
obtained results. We think this because the difference 
in body mass index between both age populations was 
insignificant and body mass index did not correlate with 
plasma levels of these adipokines. Moreover, higher 
levels of TNF-a and lower levels of adiponectin were 
found even after adjusting for body mass index. Apart 
from changes in adipose tissue, the obtained results may 
be explained by a decrease in sex hormone levels after 
menopause and in men with late-onset hypogonadism. 
Considering the role of adiponectin and TNF-a in 
the regulation of insulin sensitivity [3, 4], age-related 
changes in their plasma levels may either participate in 
the development of insulin resistance or at least reflect 
impaired receptor sensitivity.
The most interesting finding of this study was the 
observation that ezetimibe, administered alone or in 
combination with a HMG-CoA reductase inhibitor, 
affected plasma leptin and adiponectin levels in an 
age-dependent manner. In the case of simvastatin/ 
/ezetimibe combination therapy, the obtained results 
cannot be attributed to the action of simvastatin be-
cause the impact of simvastatin on circulating levels 
of all investigated adipokines did not differ between 
younger and older patients. Ezetimibe is an inhibitor 
of Niemann-Pick C1-Like 1 transporter (NPC1L1) in the 
jejunal brush border, thus decreasing intestinal choles-
terol absorption and reducing total and LDL-cholesterol 
levels [27, 28]. Although, to the best of our knowledge, 
no data are available in humans, aging was associated 
with up-regulated expression of NPC1L1 in mice [29]. 
However, the lack of correlation between ezetimibe-
induced changes in plasma lipids and the impact of 
this drug on plasma hsCRP, leptin, and adiponectin 
suggests that non-lipid-related effects of ezetimibe are 
responsible for its different effect on systemic inflamma-
tion and adipose disuse in various age groups. A cross-
talk between adipocytes and macrophages, being the 
most abundant immune cells in adipose tissue, allows 
the coordination of available energy stores for survival 
during times of starvation and pathogen challenge 
[30]. This cross-talk may change with age as a result of 
increased macrophage infiltration of adipose tissue [10]. 
Interestingly, monocyte-derived macrophage express 
NPC1L1 and other proteins bound by ezetimibe (amino 
peptidase N, annexin-2, and caveolin-1) [31, 32], while 
ezetimibe was found to reduce the number of mono-
cytes and the expression of monocyte chemoattractant 
protein-1 (MCP-1) in atherosclerotic plaques in rabbits 
[33]. It is possible that age-related changes in the num-
ber and function of macrophages may, at least partially, 
contribute to the different effect of ezetimibe in various 
age groups. Alternatively, the NPC1L1 inhibitor may 
directly affect adipocyte secretory function, and the 
various strengths of its action result from age-related 
changes in the characteristics of adipocytes.
In the whole population of patients, the effect of 
ezetimibe and simvastatin/ezetimibe combination ther-
apy on plasma adipokines and hsCRP correlated with 
its impact on HOMA-IR, while the effect of ezetimibe 
was stronger in insulin-resistant than in insulin-sensitive 
subjects [21, 22, 24]. Correlations between adipokines 
or hsCRP and insulin sensitivity in ezetimibe-treated 
patients were also observed in both younger and older 
patients, analysed in the present study, but they were 
weak. This finding as well as only an insignificant de-
crease in HOMA-IR and in TNF-a, being one of the best 
markers of insulin sensitivity, causatively linked with its 
development [3, 4], indicate that other mechanisms, not 
investigated in this study, may contribute to ezetimibe-
induced changes in hsCRP, leptin, and adiponectin, and 
suggest that a favourable effect on adipokines may be 
observed even in non-insulin-resistant older adults.
Expectedly [34], baseline levels of hsCRP were 
higher in the older group of patients, and this finding 
may be partially explained by age-related differences in 
the production of TNF-a and adiponectin. Interestingly, 
the effect of ezetimibe on this protein, being a highly 
sensitive marker of low-grade systemic inflammation 
and a protein playing a direct role in the progression 
and instability of the atherosclerotic lesions [35], was 
determined by age. This observation suggests that 
older patients may benefit more from ezetimibe treat-
ment than younger ones, particularly if they are at high 
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cardiovascular risk. However, it should be clearly stated 
that even in the group of patients aged between 51 and 
65 years, the effect of ezetimibe on hsCRP was more 
limited than that of simvastatin; therefore, ezetimibe 
can be considered as an alternative to statins only in 
individuals intolerant to statins or having contraindica-
tions to statin therapy.
We are aware of some limitations of this study. The 
major one is the small sample size and short treatment 
duration. Moreover, we only retrospectively analysed 
data of our previous studies. The measurement of circu-
lating adipokine levels does not allow us to assess their 
action at the level of visceral and subcutaneous adipose 
tissues. Finally, because all patients had elevated cho-
lesterol levels, the question whether the results would 
be the same if the study included patients with normal 
plasma lipids remains unanswered.
Conclusions
The results of the study show that the impact of 
ezetimibe and ezetimibe/simvastatin combination 
therapy partially differed between patients belong-
ing to various age groups. This finding indicates that 
age differences may partially determine the effect of 
ezetimibe, but not of simvastatin, on adipose tissue 
secretory function.
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